Clinical Trials
85 trialsOVATION-3
Imunon
DO-01
Daiichi Sankyo
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Sichuan Baili Pharmaceutical Co., Ltd.
FLORA-5
CanariaBio Inc.
KEYNOTE-B96
Merck Sharp & Dohme LLC
FOCUS / KOV-04
National Cancer Center, Korea
KOV-HIPEC-02R
National Cancer Center, Korea
TREVI-OC-01
AstraZeneca
MIRASOL
AbbVie
ATHENA
pharmaand GmbH
MITO32
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)
Shanghai Gynecologic Oncology Group
LEPRE
Ente Ospedaliero Ospedali Galliera
SORAYA
ImmunoGen, Inc.
Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer
Anhui Provincial Hospital
CATCH-R
pharmaand GmbH
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
OVAL
Vascular Biogenics Ltd. operating as VBL Therapeutics
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
OReO
AstraZeneca
Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer
West China Second University Hospital
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
FORWARD I
ImmunoGen, Inc.
A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation
Zhongnan Hospital
FOCUS
Shanghai Gynecologic Oncology Group
HIPECOV
Zhongnan Hospital
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Canadian Cancer Trials Group
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Canadian Cancer Trials Group
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
GOG Foundation
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma
Japanese Gynecologic Oncology Group
EHTASEOCCS
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
HIPOVA-01
Hospices Civils de Lyon
Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer
Peking Union Medical College Hospital
Phase III Trial of Stage I Ovarian Cancer After Surgery
Japanese Gynecologic Oncology Group
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
GOG Foundation
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms
Alliance for Clinical Trials in Oncology
Long-acting G-CSF for Febrile Neutropenia
Peking Union Medical College Hospital
hipecova
Hospital General de Ciudad Real
EHNPCTASEOC
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
TRINOVA-2
Amgen
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
OHSU Knight Cancer Institute
OVATURE
MEI Pharma, Inc.
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
AGO Study Group
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer
AGO Study Group
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
SWOG Cancer Research Network